Research programme: anti-CLEVER-1 antibodies - Faron Pharmaceuticals

Drug Profile

Research programme: anti-CLEVER-1 antibodies - Faron Pharmaceuticals

Alternative Names: Clevegen®; FP-1115; FP-1302; FP-1304; FP-1305

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Faron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action STAB1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Finland (Parenteral)
  • 06 Sep 2017 Faron Pharmaceuticals enters into an agreement with the University of Birmingham Medical School for a phase I/II clinical trial in Liver cancer
  • 06 Sep 2017 Faron Pharmaceuticals intends to submit a protocol for a clinical trial in Melanoma, Pancreatic and Ovarian cancer to the Finnish Medicines Agency by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top